Phase 3 N=512 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC
Pancreatic Adenocarcinoma
Primary: Overall Survival (OS) — 7.5; 6.7 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=30 Engage Psychotherapy to Promote Connectedness in Caregivers
Loneliness · Social Isolation · Caregiver Burnout
Primary: Loneliness — 48.76; 44.44 units on a scale
Phase 3 N=160 Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)
Neurodermatitis
Primary: Percentage of Participants With Greater Than or Equal to (>=) 4 Points Improvement (Reduction) From Baseline in Worst-Itch Numeric Rating Scale (WI-NRS) Scores at Week…
Phase 2 N=13 Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Melanoma (Skin)
Primary: Tumor Response as Measured by RECIST Criteria — 6; 7 Participants
N/A N=1,277 Project Insight: Feasibility of a Breast Cancer Screening Decision Support Tool
Breast Cancer Screening · Oncology · Preventative Medicine
Primary: Change in Total Knowledge Score of Screening Mammography Guidelines — 51.0; 47.0; 56.2; 54.6 score on a scale
N/A N=150 Chronic Total Occlusion Percutaneous Coronary Intervention Study
Chronic Total Occlusion · Ischemic Heart Disease · Chronic Total Occlusion of Coronary Artery
Primary: Number of Participants With Procedure Success — 121 Participants
Phase 2 N=4,786 Partnership for Research on Ebola VACcinations
Ebola Virus Disease
Primary: Percentage of Participants With Ebola Virus Glycoprotein (GP-EBOV) Antibody Response — 40.9; 75.7; 81.1; 2.7 percentage of participants — p=<.001
Phase 2 N=30 Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD)
Parkinson Disease
Primary: Sleep and Fatigue — 15.6; 9.0; 10.9; 6.6 units on a scale
Phase 2 N=18 Laser and Microdermabrasion Before Photodynamic Therapy for Actinic Keratoses in Field-cancerized Skin
Actinic Keratosis · Sun Damaged Skin · Solar Keratosis
Primary: Complete Clearance (%) of Actinic Keratoses (AKs) — 81; 60 percentage (%) of AK clearance
N/A N=120 TMS for Suicidal Crisis in Active Duty SMs
Suicide · Suicidal Ideation · Suicidal Impulses
Primary: Change in Suicidal Ideation (Acute) — 0.12; 0.12 score on a scale
N/A N=9 Evaluation of SmartSleep Technology for Improving the Efficiency and Restorative Quality of Sleep in Healthy Adults
Sleep
Primary: Psychomotor Vigilance Test-Brief (PVT-B) — 3.59; 4.61; 5.55; 3.95 PVT lapses — p=0.36
Phase 2 N=23 A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema
Hereditary Angioedema
Primary: Time-normalized Number of HAE Attacks (Per Month) From Week 1 to Week 17 — 2.21; 0.23; 1.52 HAE attacks per month — p=0.001
Phase 2 N=42 Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia · Recurrent Childhood B-Lymphoblastic Lymphoma
Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035
Phase 3 N=3,132 A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma
Asthma
Primary: Number of Participants With a Severe Asthma Exacerbation Event — 207; 266; 241; 276 Participants — p=<0.001
Phase 2 N=35 CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques
Edematous Fibrosclerotic Panniculopathy · Cellulite · Laxity; Skin
Primary: Percentage of 1-Level Responders (+1 or Better Score) on the Investigator-Global Aesthetic Improvement Scale (I-GAIS) for Either Buttock or Either Thigh — 85.7; 87.5…